Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin.

ABSTRACT:

Abstract

BackgroundGlioma patients may require long-term anticoagulation for comorbidities, including arrhythmias or venous thromboembolism (VTE). While direct oral anticoagulants (DOACs) have demonstrated safety in general cancer populations, safety data for glioma patients remains limited. The aim of this study was to assess intracerebral hemorrhage (ICH) risk with DOAC compared to low molecular weight heparin (LMWH) in glioma patients.

Methods

We reviewed adult patients with primary glioma who received DOAC and/or LMWH for at least 10 days between 2008 and 2023 across Cleveland Clinic Health System hospitals. ICH rates and severity were compared between treatment groups.

Results

Among 277 patients (147 DOAC, 130 LMWH), median time from tumor diagnosis to first VTE

SUBMITTER: Amin RS 

PROVIDER: S-EPMC12746604 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature